Positive News SentimentPositive NewsNASDAQ:TARA Protara Therapeutics (TARA) Stock Price, News & Analysis $4.06 +0.04 (+0.95%) As of 11:01 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protara Therapeutics Stock (NASDAQ:TARA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Protara Therapeutics alerts:Sign Up Key Stats Today's Range$4.04▼$4.1450-Day Range$3.65▼$4.9752-Week Range$2.97▼$7.82Volume128,378 shsAverage Volume872,169 shsMarket Capitalization$228.06 millionP/E RatioN/ADividend YieldN/APrice Target$26.25Consensus RatingModerate Buy Company Overview Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease. Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells. By engaging OX40, PTX-35 aims to amplify anti-tumor T-cell responses and promote durable immunity against viral antigens. The company has also advanced preclinical vaccine programs targeting high-grade cervical dysplasia driven by HPV-16 and HPV-18, with the goal of reducing the need for surgical intervention. Headquartered in San Diego, California, Protara conducts early-stage clinical trials in North America and collaborates with academic research centers to explore combination regimens and next-generation immuno-oncology approaches. As a Nasdaq-listed company under the ticker TARA, Protara Therapeutics continues to build its pipeline through internal research and strategic partnerships aimed at addressing unmet needs in virus-associated oncology.AI Generated. May Contain Errors. Read More Protara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreTARA MarketRank™: Protara Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 420th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingProtara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialProtara Therapeutics has a consensus price target of $26.25, representing about 553.0% upside from its current price of $4.02.Amount of Analyst CoverageProtara Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.44) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protara Therapeutics is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protara Therapeutics is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtara Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Protara Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.75% of the float of Protara Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtara Therapeutics has a short interest ratio ("days to cover") of 6.72.Change versus previous monthShort interest in Protara Therapeutics has recently increased by 4.76%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtara Therapeutics does not currently pay a dividend.Dividend GrowthProtara Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment1.54 News SentimentProtara Therapeutics has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for TARA on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows2 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Protara Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.60% of the stock of Protara Therapeutics is held by insiders.Percentage Held by Institutions38.13% of the stock of Protara Therapeutics is held by institutions.Read more about Protara Therapeutics' insider trading history. Receive TARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARA Stock News HeadlinesProtara Therapeutics Announces Key Medical Leadership TransitionJune 29, 2026 | tipranks.comFoghorn Therapeutics (FHTX) Receives a Buy from H.C. WainwrightMay 21, 2026 | theglobeandmail.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.July 27 at 1:00 AM | Chaikin Analytics (Ad)Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHAMay 20, 2026 | globenewswire.comProtara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations TranscriptMay 19, 2026 | seekingalpha.comProtara’s cell therapy shows treatment durability in mid-stage NMIBC studyMay 19, 2026 | msn.comProtara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical ProgramMay 18, 2026 | quiverquant.comQProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026May 18, 2026 | globenewswire.comSee More Headlines TARA Stock Analysis - Frequently Asked Questions How have TARA shares performed this year? Protara Therapeutics' stock was trading at $5.33 at the beginning of 2026. Since then, TARA shares have decreased by 24.6% and is now trading at $4.02. How were Protara Therapeutics' earnings last quarter? Protara Therapeutics, Inc. (NASDAQ:TARA) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.05. When did Protara Therapeutics IPO? Protara Therapeutics (TARA) raised $79 million in an IPO on Wednesday, October 22nd 2014. The company issued 6,110,000 shares at $12.00-$14.00 per share. Who are Protara Therapeutics' major shareholders? Top institutional shareholders of Protara Therapeutics include Assenagon Asset Management S.A. (0.11%). Insiders that own company stock include Jacqueline Zummo, Jacqueline Zummo and Opaleye Management Inc. View institutional ownership trends. How do I buy shares of Protara Therapeutics? Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Digital Turbine (APPS), SoFi Technologies (SOFI), Canoo (GOEV), ChargePoint (CHPT) and CrowdStrike (CRWD). Company Calendar Last Earnings5/13/2026Today7/27/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 TARA's financial health is in the Yellow zone, according to TradeSmith. TARA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TARA Previous SymbolNASDAQ:PRTO CIK1359931 Webwww.proteontherapeutics.com Phone(646) 844-0337Fax781-487-6729Employees30Year Founded2017Price Target and Rating Average Price Target for Protara Therapeutics$26.25 High Price Target$28.00 Low Price Target$24.00 Potential Upside/Downside+541.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.70% Return on Assets-36.02% Debt Debt-to-Equity RatioN/A Current Ratio15.69 Quick Ratio15.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book1.08Miscellaneous Outstanding Shares56,200,000Free Float51,932,000Market Cap$229.86 million OptionableOptionable Beta1.48 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TARA) was last updated on 7/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARA Stock Alerts